Biblio
Donor-derived malignancy and transplant morbidity: Risks of patient and donor genetics in allogeneic hematopoietic stem cell transplant: Donor-derived malignancy and genetic risks in allo-HSCT. Transplant Cell Ther. 2023.
Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis. Blood Adv. 2023.
A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. Blood Adv. 2023.
The two-step approach to allogeneic hematopoietic stem cell transplantation. Front Immunol. 2023;14:1237782.
. Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies. Hematol Oncol Stem Cell Ther. 2022;15(3):112-116.
. Chimeric Antigen Receptor T Cell Therapy For Solid Tumors. Hematol Oncol Stem Cell Ther. 2022;15(3):94-99.
. Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement. Hematol Oncol Stem Cell Ther. 2022;15(3):66-72.
. Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia. Hematol Oncol Stem Cell Ther. 2022;15(3):131-136.
. Next-Generation Chimeric Antigen Receptor T-cells. Hematol Oncol Stem Cell Ther. 2022;15(3):117-121.
. Optimizing Utilization of Blood Products in the Hematologic Malignancy Clinic: Less Is More. JCO Oncol Pract. 2022:OP2100575.
. Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors. Biol Blood Marrow Transplant. 2020.
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
Ofatumumab for posttransplant lymphoproliferative disorder. Hematol Oncol Stem Cell Ther. 2020.
. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients. Biol Blood Marrow Transplant. 2020.
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020.
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3(20):3123-3131.
The concentration of total nucleated cells in harvested bone marrow for transplantation has decreased over time. Biol Blood Marrow Transplant. 2019.
Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019.
OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANT FOR ELDERLY PATIENTS WITH HEMATOLOGIC MALIGNANCIES. Biol Blood Marrow Transplant. 2019.
.